ASH 2021 Sickle Cell News
Advertisement
Patients with hematologic malignancies who may require blood transfusions may not be able to enroll in hospice care.
This clinical outcome translates to meaningful improvement in health-related quality of life, according to researchers.
Researchers evaluated the effects of etavopivat in two-week multiple ascending dose cohorts and a 12-week open-label study.
Researchers found no increased risk for acute deep vein thrombosis post-vaccination for approved COVID-19 vaccines.
Lead author Jacqueline N. Poston, MD, shared the findings.
The present analysis updates findings from the ongoing phase 1/2 HGB-206 study.
Researchers described the outcomes for pregnant women with SCD, who are considered at high risk for complications.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.